Managing Patients with Psoriasis and Comorbidities

0 reviews

Haymarket Medical Education

1 hour

PROGRAM DESCRIPTION
Psoriasis is a common chronic inflammatory skin condition that affects 3% to 4% of adults in the United States. Genetic susceptibility, immune dysregulation, and environmental factors are all thought to play a role in the development of the condition. Immunopathogenic studies have revealed that tumor necrosis factor alpha (TNF-α) and interleukins (IL-12, IL-17, IL-22, IL-23) are key cytokines involved in the pathogenesis of psoriasis. In recent years, there has been a focus on the development of treatment agents targeting these inflammatory cytokines. Despite the availability of effective treatments for psoriasis, physicians often fail to recognize psoriasis as a systemic inflammatory disease, resulting in significant undertreatment. Specifically, moderate and severe psoriasis are often treated with topical agents rather than more potent biologic and oral treatments, contributing to suboptimal outcomes and poor patient satisfaction. In this CME Outfitters webinar, participants will be presented with a real-world case scenario intermixed with nationally-known, expert faculty discussing the latest clinical data, guidelines, and quality measures and how they apply to the case as we add layers of complexity to our patient scenario. Finally, faculty will discuss creating personalized clinical action plans for patients with psoriasis and take questions during dedicated time for Q & A.

EDUCATIONAL OBJECTIVES
At the end of this CE activity, participants should be able to:Physicians:Describe the pathophysiologic pathways underlying psoriasis and the rationale for treatment selection based on the MOA of agents that target these pathwaysIdentify the comorbidities common in patients with psoriasis and the impact of these comorbidities on treatment selectionSelect appropriate treatments for patients with psoriasis based on disease characteristics, and efficacy and safety profiles of treatmentsCNE/CPE:Describe the pathophysiologic pathways underlying psoriasis and the rationale for treatment selection based on the MOA of agents that target these pathwaysIdentify the comorbidities common in patients with psoriasis and the impact of these comorbidities on treatment selectionDescribe appropriate treatments for patients with psoriasis based on disease characteristics, and efficacy and safety profiles of treatment